ClinicalTrials.gg
RecruitingNCT06914713Updated Oct 16, 2026

Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF

An interventional study of Jin-shui Huan-xian granule and Jin-shui Huan-xian granule placebo in Idiopathic Pulmonary Fibrosis(IPF), sponsored by Henan University of Traditional Chinese Medicine. Recruiting at 1 site in China. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Henan University of Traditional Chinese Medicine · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 16, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
384
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.

Planned enrollment
11th of 60
384 · median 83
Started
2025
with 9 others
No phase
3 of 67
2 open now
Primary completion
2027-12
later than 13 of 28 live
Registered
47th of 67
by date
Lead sponsor
4 of 67
Henan University of Traditional Chinese Medicine

Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 11th largest by planned enrollment of the 60 interventional ones that give a count, is one of 10 that started in 2025, is one of 3 with no phase, reaches primary completion later than 13 of the 28 other live ones, and was the 47th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

This study is to evaluate the clinical efficacy and safety of Jin-shui Huan-xian Formula in retarding the decline of pulmonary function in IPF, generate high - quality clinical evidence, and establish a treatment plan of Jin-shui Huan-xian Formula for retarding the decline of pulmonary function in Idiopathic Pulmonary Fibrosis(IPF)

Read the detailed description

This study will enroll 384 patients with idiopathic pulmonary fibrosis (IPF) and adopts a randomized, quadruple-masked, placebo-controlled trial design. Participants will be randomly assigned to either an experimental group or a control group. On the basis of guideline-directed standard treatment, the experimental group will receive Jin-shui Huan-xian Formula, while the control group will receive a matching placebo. Participants, care providers, investigators, and outcome assessors will remain blinded to treatment allocation. The treatment duration is 52 weeks. Forced vital capacity (FVC) is the primary outcome measure, while acute exacerbations, other pulmonary function parameters (including DLCO and DLCO%), exercise capacity, and quality of life are secondary outcome measures. Safety assessments include routine blood tests, urinalysis, liver function, renal function, and electrocardiography. The study aims to evaluate the efficacy and safety of Jin-shui Huan-xian Formula in slowing the decline in pulmonary function in patients with IPF and to generate high-quality clinical evidence for its use as an adjunctive treatment.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis(IPF)

Keywords

  • Idiopathic Pulmonary Fibrosis
  • traditional Chinese medicine
  • randomized controlled trial
  • pulmonary function
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who meet the diagnostic criteria for IPF.
  2. Pulmonary function: The percentage of forced vital capacity (FVC) to the predicted value is ≥ 50%; and the percentage of the diffusing capacity of the lung for carbon monoxide (DLCO) to the predicted value is ≥ 30%.
  3. Patients who meet the syndrome - differentiation criteria for lung - qi deficiency syndrome, lung - and - kidney qi deficiency syndrome, etc.
  4. Aged between 40 and 85 years old.
  5. Patients who voluntarily accept the treatment and sign the

Exclusion criteria

Exclusion Criteria:

  1. Patients in the acute exacerbation phase of IPF.
  2. Patients complicated with other pulmonary diseases such as (COPD), lung cancer, active pulmonary tuberculosis, bronchiectasis, and pulmonary embolism.
  3. Patients with severe joint, peripheral nerve, and peripheral vascular diseases that affect limb movement and who are bed - ridden for a long time and cannot complete the six - minute walk test.
  4. Patients complicated with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, heart function grade 3 or above, stroke, cerebral hemorrhage, etc.).
  5. Patients complicated with liver diseases such as cirrhosis or secondary portal hypertension, bleeding caused by esophageal and gastric varices, patients with kidney diseases requiring dialysis or kidney transplantation, or patients with abnormal liver and kidney functions (, AST, and BUN are 1.5 times higher than the , and blood Cr is higher than the upper limit of the normal range).
  6. Patients with unclear consciousness, various mental illnesses, etc., who cannot communicate normally.
  7. Pregnant or lactating women and patients with a recent plan for pregnancy.
  8. Patients who have participated in other clinical trials within 1 month before enrollment.
  9. Patients known to be allergic to any of the test medications and their components.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
384 participants (estimated)

Study arms

  • Experimental
    Jin-shui Huan-xian granule in addition to the guideline - directed treatment.

    The experimental group was given Jin-shui Huan-xian Formula in addition to the treatment guided by the guideline "Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline ".

    Drug: Jin-shui Huan-xian granule

  • Placebo comparator
    Jin-shui Huan-xian granule placebo in addition to the guideline - directed treatment.

    Participants in the control group will receive Jin-shui Huan-xian granule placebo in addition to guideline-directed treatment based on the "Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

    Drug: Jin-shui Huan-xian granule placebo

Interventions

  • DrugJin-shui Huan-xian granule

    Jin-shui Huan-xian Granules: on the basis of treatment guided by "Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline ", the experimental group was given Jin-shui Huan-xian Granules for treatment. The granules were taken orally, 1 dose per day, twice a day, and the continuous administration lasted for 52 weeks.

    Also known as: Jin-shui Huan-xian Granules

  • DrugJin-shui Huan-xian granule placebo

    Jin-shui Huan-xian granule placebo: on the basis of treatment guided by "Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline ", the experimental group was given Jin-shui Huan-xian Granules placebo for treatment. The granules were taken orally, 1 dose per day, twice a day, and the continuous administration lasted for 52 weeks.The Jin-shui Huan-xian granules and their placebo are identical in appearance, weight, color and smell.

06

What researchers measure

Primary outcomes

  1. Forced vital capacity (FVC)

    FVC will be used to assess pulmonary function.

    Time frame: The change in absolute FVC value before treatment and at 52 weeks of treatment

Secondary outcomes

  1. The time of the first acute exacerbation

    The time of the patients' first acute exacerbation will be recorded.

    Time frame: Up to week 52.

  2. Frequency of acute exacerbation

    Frequency of acute exacerbation will be recorded.

    Time frame: Up to week 52

  3. Frequency of acute exacerbations resulting in hospitalization

    Frequency of acute exacerbation resulting in hospitalization will be recorded.

    Time frame: Up to week 52

  4. Frequency of acute exacerbations resulting in ICU admission

    Frequency of acute exacerbation resulting in ICU admission will be recorded.

    Time frame: Up to week 52

  5. Annual acute exacerbation rate

    The annual acute exacerbation rate will be calculated in each group at the end of the trial.

    Time frame: Up to week 52

  6. Annual hospitalization rate due to acute exacerbation

    The Annual hospitalization rate due to acute exacerbation will be calculated in each group at the end of the trial.

    Time frame: Up to week 52

  7. Annual rate of ICU admission due to acute exacerbation

    The Annual ICU admission rate due to acute exacerbation will be calculated in each group at the end of the trial.

    Time frame: Up to week 52.

  8. Diffusing Capacity of Carbon Monoxide(DLCO)

    DLCO will be used to assess pulmonary function.

    Time frame: Change from baseline DLCO at week 13, 26, 39 and 52.

  9. Percent of Diffusing Capacity of Carbon Monoxide(DLCO%)

    DLCO% will be used to assess pulmonary function.

    Time frame: Change from baseline DLCO% at week 13, 26, 39 and 52.

  10. Percent of Forced Vital Capacity(FVC%)

    FVC% will be used to assess pulmonary function.

    Time frame: Change from baseline FVC%at week 13, 26, 39 and 52.

  11. Alveolar ventilation(VA)

    VA will be used to assess pulmonary function.

    Time frame: Change from baseline VA at week 13, 26, 39 and 52.

  12. .Diffusion capacity for carbon monoxide per liter of alveolar volume(DLCO/VA)

    DLCO/VA will be used to assess pulmonary function.

    Time frame: Change from baseline DLCO/VA at week 13, 26, 39 and 52.

  13. All-cause mortality rate

    The all-cause mortality rate will be calculated in each group at the end of the trial.

    Time frame: Up to week 52.

  14. Mortality rate due to acute exacerbation

    The mortality rate due to acute exacerbation will be calculated in each group at the end of the trial.

    Time frame: Up to week 52.

  15. Progression-Free Survival(PFS)

    According to "Idiopathic Pulmonary Fibrosis in Adults (Update) and Progressive Pulmonary Fibrosis: An Official Clinical Practice Guideline of the ATS/ERS/JRS/ALAT ": The time from enrollment to the first meeting of disease progression (at least two of respiratory symptoms, physiological evidence and radiological evidence).

    Time frame: Up to week 13, 26, 39 and 52.

  16. Six Minute Walk Test (6MWT)

    6MWT will be applied to evaluate the exercise capacity. The higher values indicate the better exercise capacity.

    Time frame: Change from baseline 6MWT at week 13, 26, 39 and 52.

  17. Imaging findings

    Changes in chest CT imaging will be assessed before and after JSHX treatment to evaluate its impact on pulmonary fibrosis in IPF patients. High-resolution computed tomography (HRCT) will be used to quantify alterations in lung parenchyma, including ground-glass opacities, reticulation, and honeycombing. Quantitative software-based analysis (e.g., histogram-based texture analysis) may be applied to standardize the evaluation. Radiologists blinded to treatment allocation will independently review the images to ensure objectivity.

    Time frame: Up to week 26, 52.

  18. A Tool to Assess Quality of life (ATAQ-IPF)

    ATAQ - IPF is currently a specialized scale for evaluating the quality of life of patients, consisting of 13 dimensions and 74 items, with each item being scored from 1 to 5 points. A higher score indicates a worse condition.

    Time frame: Change from baseline ATAQ-IPF scores at week 13, 26, 39 and 52.

  19. Idiopathic pulmonary fibrosis patient reported outcomes (IPF-PRO)

    IPF-PRO is a scale used to evaluate the quality of life of patients, where patients recall their condition over the past two weeks based on their subjective experience. The evaluation covers four domains: Physiological, Psychological, Environmental, and Satisfaction, comprising 18 items in total. Higher scores indicate worse conditions.

    Time frame: Change from baseline SGRQ scores at week 13, 26, 39 and 52.

  20. Dyspnea

    Dyspnea will be assessed by 22.modified Medical Research Council(mMRC) scores. A score of 0-4 will be given according to the degree of immediate dyspnea. A higher score indicates a worse condition.

    Time frame: Change from baseline CAT scores at week 13, 26, 39 and 52.

  21. Cough Visual analog scale(VAS)

    The Cough VAS is a method of quantitatively assessing cough symptoms using the Visual Analogue Scale. The score ranges from 1 to 100, a higher score indicates a worse condition.

    Time frame: Change from baseline CAT scores at week 13, 26, 39 and 52.

  22. Clinical symptoms and Signs

    Clinical symptoms and Signs will be evaluated through a scale. The scale includes coughing, expectoration, chest tightness, shortness of breath, wheezin. The Clinical Symptom Rating Scale includes 6 items: cough, expectoration, chest tightness, shortness of breath, wheezing, and cyanosis. Each item has a score of 0-3, totaling 18 points. The higher the score, the worse he patient's condition.

    Time frame: Change from baseline clinical symptoms and signs up at week 13, 26, 39 and 52.

  23. Krebs Von den Lungen-6 (KL-6)

    Detect the level of KL-6.

    Time frame: Change from baseline KL-6 level at week 13, 26, 39 and 52.

  24. Interleukin-6 (IL-6)

    Detect the level of IL-6.

    Time frame: Change from baseline IL-6 level at week 13, 26, 39 and 52.

  25. Ferritin

    Detect the level of Ferritin.

    Time frame: Change from baseline Ferritin level at week 13, 26, 39 and 52.

  26. Immunoglobulin

    Detect the level of immunoglobulins

    Time frame: Change from baseline immunoglobulins level at week 13, 26, 39 and 52.

  27. T, B and NK lymphocyte subsets

    Detect the level of T, B and NK lymphocyte subsets. The common indicators of TBNK lymphocyte subsets and their respective units of measurement are as follows: the total T cells (CD3+), measured in cells per microliter (cells/µL); the helper T cells (CD3+CD4+), measured in cells/µL; the cytotoxic T cells (CD3+CD8+), measured in cells/µL; the B cells (CD19+), measured in cells/µL; the natural killer cells (NK cells, CD16+CD56+, CD3-), measured in cells/µL; and the CD4/CD8 ratio, which is a unitless ratio. These indicators are detected by flow cytometry and can reflect the immune function status of the body.

    Time frame: Change from baseline T, B and NK lymphocyte subsets level at week 13, 26, 39 and 52.

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.

Of 49 non-industry interventional studies with no phase under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 53. This study's planned 27 months is close to that.

Counting every sponsor, half of 52 studies reached it within 26 months; a quarter within 12 and three quarters within 53.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Aug 2025 → Sep 2025 and primary completion Jun 2028 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2025
First posted
Apr 6, 2025
StartActual
Sep 8, 2025was Aug 2025
Primary completionEst.
Dec 30, 2027was Jun 2028
CompletionEst.
Nov 30, 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
the First Affiliated Hospital of Henan University of Chinese Medicine is now Recruiting
Oct 16, 2026
Start date
Aug 1, 2025→Sep 8, 2025 (actual)
Oct 16, 2026
Primary completion
Jun 30, 2028→Dec 30, 2027
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    the First Affiliated Hospital of Henan University of Chinese Medicine is now Recruiting
    Start date Aug 1, 2025→Sep 8, 2025 (now actual)
    Primary completion Jun 30, 2028→Dec 30, 2027
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06914713
Lead sponsor
Henan University of Traditional Chinese Medicine
Responsible party
Sponsor
First posted
Apr 6, 2025
Start date
Sep 8, 2025
Primary completion
Dec 30, 2027 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Ming-Hang Wang, Ph.D
Contact
wmh107hn@163.com
+8618638392188
Xue-qing Yu, Ph.D
Contact
yxqshi@163.com
+8613525518843

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion